• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S B (OP: NONOF )

    133.54 +3.11 (+2.39%)
    Streaming Delayed Price Updated: 3:38 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,270
    Open 135.00
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 130.43
    Today's Range 129.16 - 136.19
    52wk Range 86.75 - 201.98
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
    The greater weight loss in women did not result in significantly better improvements in heart failure symptoms. 
    Via Benzinga
    Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
    As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide. 
    Via Benzinga

    Performance

    YTD
    +31.96%
    +31.96%
    1 Month
    +11.75%
    +11.75%
    3 Month
    -6.17%
    -6.17%
    6 Month
    +1.45%
    +1.45%
    1 Year
    -31.53%
    -31.53%

    More News

    Read More
    The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
    Via InvestorPlace
    Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
    Via Benzinga
    7 Mutual Funds That Will Outperform in Any Market
    Via InvestorPlace
    Did Ozempic Play A Role In A Man's Suicide? Family Seeks Warning Label
    Via Benzinga
    Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector
    Via Benzinga
    Experts Weigh In On Ozempic's Evolving Side Effects And How To Handle Them
    Via Benzinga
    Diabetes Drug Ozempic May Hold Key to Breaking Addictions: The Guardian
    Via Benzinga
    Icannex Taps Ex Pfizer, FDA & Regulatory Affairs Expert
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.